Why the study?
Somatic KCNJ5 mutations had not been reported in patients with glucocorticoid-remediable aldosteronism, leaving the appropriate treatment and prognosis of such concurrent cases unknown.
Does unilateral adrenalectomy cure hypertension in patients with familial hyperaldosteronism type I and somatic KCNJ5 mutations?
Does unilateral adrenalectomy cure hypertension in patients with familial hyperaldosteronism type I and somatic KCNJ5 mutations?
Unilateral adrenalectomy can provide a complete clinical cure for hypertension in patients with glucocorticoid-remediable aldosteronism who have concurrent somatic KCNJ5 mutations.
May support surgical evaluation in glucocorticoid-remediable aldosteronism with KCNJ5 mutations; hypothesis-generating and requires prospective validation.
CONTEXT: Familial hyperaldosteronism type I (FH-I) or glucocorticoid-remediable aldosteronism (GRA) is caused by unequal crossing over of the steroid 11β-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) genes. Somatic KCNJ5 mutations have not been reported in patients with GRA; therefore, the appropriate treatment and prognosis of such concurrent cases remain unknown. CASE DESCRIPTION: Two siblings of a Taiwanese family with GRA were found to have adrenal adenomas and somatic KCNJ5 mutations. Complete clinical cure was achieved after unilateral adrenalectomy. Furthermore, the conversion site of the chimeric gene was identified by direct sequencing. CONCLUSIONS: We report the coexistence of a somatic KCNJ5 mutation and GRA. Patients with GRA whose blood pressure management develops resistance to glucocorticoid treatment could therefore benefit from a lateralization test. The promising outcomes after unilateral adrenalectomy presented in this report offer new perspectives for further research into various PA subtypes.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: